A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.

被引：1
|
作者：
Shitara, Kohei
Yonesaka, Kimio
Denda, Tadamichi
Yamazaki, Kentaro
Moriwaki, Toshikazu
Tsuda, Masahiro
Takano, Toshimi
Okuda, Hiroyuki
Nishina, Tomohiro
Sakai, Kazuko
Nishio, Kazuto
Tokunaga, Shoji
Yamanaka, Takeharu
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3567
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G
    Shitara, Kohei
    Yonesaka, Kimio
    Denda, Tadamichi
    Yamazaki, Kentaro
    Moriwaki, Toshikazu
    Tsuda, Masahiro
    Takano, Toshimi
    Okuda, Hiroyuki
    Nishina, Tomohiro
    Sakai, Kazuko
    Nishio, Kazuto
    Tokunaga, Shoji
    Yamanaka, Takeharu
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    CANCER SCIENCE, 2016, 107 (12) : 1843 - 1850
  • [2] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Cohn, Allen Lee
    Hecht, J. Randolph
    Dakhil, Shaker
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)
    Naoki Izawa
    Kohei Shitara
    Kimio Yonesaka
    Takeharu Yamanaka
    Takayuki Yoshino
    Yu Sunakawa
    Toshiki Masuishi
    Tadamichi Denda
    Kentaro Yamazaki
    Toshikazu Moriwaki
    Hiroyuki Okuda
    Chihiro Kondoh
    Tomohiro Nishina
    Akitaka Makiyama
    Hideo Baba
    Hironori Yamaguchi
    Masato Nakamura
    Ichinosuke Hyodo
    Kei Muro
    Takako Eguchi Nakajima
    Targeted Oncology, 2020, 15 : 623 - 633
  • [4] Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)
    Izawa, Naoki
    Shitara, Kohei
    Yonesaka, Kimio
    Yamanaka, Takeharu
    Yoshino, Takayuki
    Sunakawa, Yu
    Masuishi, Toshiki
    Denda, Tadamichi
    Yamazaki, Kentaro
    Moriwaki, Toshikazu
    Okuda, Hiroyuki
    Kondoh, Chihiro
    Nishina, Tomohiro
    Makiyama, Akitaka
    Baba, Hideo
    Yamaguchi, Hironori
    Nakamura, Masato
    Hyodo, Ichinosuke
    Muro, Kei
    Nakajima, Takako Eguchi
    TARGETED ONCOLOGY, 2020, 15 (05) : 623 - 633
  • [5] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second -line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
    Hecht, J. Randolph
    Cohn, Allen Lee
    Dakhil, Shaker R.
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Cohn, Allen
    Dakhil, Shaker
    Saleh, Mansoor
    Piperdi, Bilal
    Cline-Burkhardt, Mika
    Tian, Ying
    Go, William Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (02) : 72 - 80
  • [7] Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)
    Peeters, Marc
    Oliner, Kelly S.
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew
    Wilson, Gregory
    Ciuleanu, Tudor-Eliade
    Roman, Laslo
    Van Cutsem, Eric
    Tian, Ying
    Jung, Andre Scott
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors
    Cohn, A. L.
    Krishnan, K.
    Hecht, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC)
    Schwartzberg, Lee Steven
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Yu, Hua
    Oliner, Kelly S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
    Peeters, Marc
    Oliner, Kelly Smith
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew
    Wilson, Gregory
    Ciuleanu, Tudor E.
    Roman, Laslo
    Van Cutsem, Eric
    Yu, Hua
    Jung, Andre Scott
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345